1423-63-8

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C10H7BrOS/c1-6(12)9-5-13-10-3-2-7(11)4-8(9)10/h2-5H,1H3

Upstream product

• 4923-87-9 5-bromobenzo[b]thiophene 
• 75-36-5 acetyl chloride 
• 118780-12-4 1-bromo-4-[2,2-(dimethoxy)ethylsulfanyl]benzene 
• 106-53-6 para-bromobenzenethiol 
• 108-24-7 acetic anhydride 

Downstream Products

• 16304-39-5 5-hydroxybenzo[b]thiophene-3-carboxylic acid 
• 123392-43-8 5-methoxy-3-benzo[b]thiophenecarboxylic acid 
• 7312-24-5 5-bromobenzo[b]thiophene-3-carboxylic acid 

Relevant academic research and scientific papers

Iminothiadiazine dioxide derivative and usage thereof

The invention discloses an iminothiadiazine dioxide derivative and usage thereof, and particularly relates to a novel iminothiadiazine dioxide derivative and a pharmaceutical composition comprising the compound. The iminothiadiazine dioxide derivative and

Hydrogen bond donor solvents enabled metal and halogen-free Friedel–Crafts acylations with virtually no waste stream

We have developed a metal and halogen-free Friedel–Crafts acylation protocol with virtually no waste stream generation. We propose a hydrogen bonding donor solvent will form a hydrogen bonding network and may provide significant rate enhancement for Friedel–Crafts reactions. Trifluoroacetic acid is one of the strongest H-bond donor solvents, which is also volatile and can be easily recovered by distillation without need for reaction workup. Our protocol is a ‘green’ Friedel–Crafts acylation process: 1) the catalyst can be recovered and reused; 2) using halogen free starting material (carboxylic acids anhydride or carboxylic acids); 3) no need for aqueous reaction work-up; 4) minimum or no waste steam generation.

FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS

In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ?2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of

Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-dimethylbicyclo[3.1.1]heptane derivatives

In an earlier paper, we reported that novel prostaglandin D2 (PGD2) receptor antagonists having the bicyclo[2.2.1]heptane ring system as a prostaglandin skeleton were a potent new class of antiallergic agents and suppressed various allergic inflammatory responses such as those observed in conjunctivitis and asthma models. In the present study, we synthesized PGD2 receptor antagonists having the 6,6-dimethylbicyclo [3.1.1]heptane ring system. These derivatives have the amide moiety, in contrast to those with the bicyclo[2.2.1]heptane ring system, which have the sulfonamide group. The derivatives having the 6,6-dimethylbicyclo[3.1.1]heptane ring also exhibited strong activity in PGD2 receptor binding and cAMP formation assays. In in vivo assays such as allergic rhinitis, conjunctivitis, and asthma models, these series of derivatives showed excellent pharmacological profiles. In particular, compound 45 also effectively suppressed eosinophil infiltration in allergic rhinitis and asthma models. This compound (45, S-5751) is now being developed as a promising alternative antiallergic drug candidate.